Asset Details
Do you wish to reserve the book?
Role of gut microbiota‐derived metabolites in neurodegenerative disorders involving protein misfolding and C9orf72 expansion associated with dementia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Role of gut microbiota‐derived metabolites in neurodegenerative disorders involving protein misfolding and C9orf72 expansion associated with dementia
Do you wish to request the book?
Role of gut microbiota‐derived metabolites in neurodegenerative disorders involving protein misfolding and C9orf72 expansion associated with dementia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Role of gut microbiota‐derived metabolites in neurodegenerative disorders involving protein misfolding and C9orf72 expansion associated with dementia
2025
Overview
Background There is growing evidence that in many neurodegenerative disorders, cell‐to‐cell transmission of a pathological, misfolded protein, such as misfolding of α‐synuclein (α‐syn) in Parkinson’s disease (PD), may be a vehicle for the spreading of pathology throughout the brain. This misfolded protein, or seed, further induces misfolding of native proteins within the cell. Pathological misfolded proteins may exist in diverse conformations with distinct cellular and biochemical properties. We investigate whether microbiota‐derived metabolites may help attenuate the misfolding of α‐syn and thereby promote resilience against PD phenotypes. We identified six biologically available gut microbiota‐derived compounds (GMP10, GMP11, GMP26, GMP28, GMP39, and GMP44) for investigation. Method Using independent in vitro protein aggregation assays (e.g., photo‐induced cross‐linking of unmodified proteins assay, thioflavin‐T, fluorescence assay, and electron microscopy), we demonstrated that three of the compounds (GMP26, GMP44, GMP28), potently inhibit aggregations of monomeric α‐syn (or monomeric β‐amyloid peptides) into neurotoxic protein aggregates, in vitro. Result Based on evidence linking the c9orf72 gene with expansions of GGGGCC hexanucleotide repeats and PD, as well as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), we continue to test the neuroprotective ability of our compounds in vivo using a Drosophila model with overexpression of GGGGCC hexanucleotide repeats. Overexpression of 30 GGGGCC repeats in the Drosophila eye causes age‐dependent photoreceptor neurodegeneration. We treated Drosophila by mixing individual test compounds into the food. We found all six compounds significantly suppressed eye degeneration at 10 µM, with compounds GMP26 and GMP11 almost completely suppressing the eye phenotype. The comparative efficacy of the six compounds are GMP26 = GMP11 > GMP39 > GMP10 > GMP44 > GMP28. Conclusion Outcomes from our studies link gut microbiota with mechanisms underlying PD and suggest the feasibility of developing GMP26 as a means to simultaneously target both α‐syn misfolding and C9orf72 expansion to increase the likelihood of therapeutic efficacy in PD, ALS, FTD patients with C9orf72 expansion.
Publisher
John Wiley & Sons, Inc
Subject
